Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples